Markets surged this week as the Nasdaq gained 4.08%, even as NVIDIA grapples with a $500 billion valuation drop and an FBI investigation into its ties with Megaspeed.
Roughly $500 billion has been wiped from Nvidia's market value since Friday, November 6, 2026, with the share price near a yearly low. Allegations tie the company to Megaspeed, suspected of helping China evade export controls, and the company hired Wachtell, Lipton, Rosen & Katz on November 10 while the FBI runs its own probe. An active federal investigation is a clear overhang, though the chip-led Nasdaq rally shows buyers are still stepping in.
Enbridge's Q3 GAAP earnings more than doubled to $1.3 billion, or $0.59 per share, from $0.7 billion, or $0.30, a year earlier, with adjusted EBITDA up to $4.4 billion from $4.3 billion. It reaffirmed 2026 guidance, placed over $3 billion of projects into service, closed the US$0.6 billion Salt Creek acquisition and announced a US$2.6 billion Tallgrass deal, with a $38 billion backlog supporting growth.
Hims & Hers signed an agreement with Eli Lilly to offer Zepbound at $299 per month and Foundayo at $149 per month through its platform, with prescriptions shipped directly to patients' homes. This gives the telehealth platform legitimate access to Lilly's GLP-1 medicines, a revenue driver, though it requires abandoning compounded copies of those drugs.
Lilly is expanding distribution of Zepbound and Foundayo through the Hims & Hers platform with self-pay pricing from $149 to $299 per month, opening a direct-to-consumer channel for its GLP-1 medicines. The commercial terms are concrete, but the revenue contribution is not quantified, limiting the certainty of a price move.
Sun Life's Q3 showed a clear split: underlying net income rose 9% to $1,146 million with underlying EPS of $2.05, up 10%, and the dividend was raised from $0.96 to $1.00 per share. But reported net income fell 29% to $785 million and reported ROE dropped to 13.0% from 19.3%. The positives and negatives largely offset, leaving the net direction uncertain.
The Nasdaq Composite climbed 4.08% this week, leading a broad market advance despite significant pressure on NVIDIA. While chip-led gains boosted indices, NVIDIA faces a federal probe and a $500 billion market value decline since November 6, 2026, following allegations regarding export control evasion.
A law firm notice cites allegations involving Nvidia's relationship with a firm called Megaspeed, suspected of helping China evade export controls. Nvidia hired an outside law firm on November 10, 2026 to investigate, and the FBI is also probing the matter.
About $500 billion in stock market value since Friday, November 6, 2026, with the share price down almost to a yearly low.
GAAP earnings attributable to common shareholders were $1.3 billion, or $0.59 per share, up from $0.7 billion, or $0.30, a year earlier. Adjusted earnings were $1.1 billion, or $0.49 per share, and adjusted EBITDA rose to $4.4 billion from $4.3 billion. The company reaffirmed its 2026 guidance.
They agreed to expand access to Zepbound and Foundayo through the Hims & Hers platform, with self-pay pricing starting at $299 per month for Zepbound and $149 per month for Foundayo, shipped directly to patients after an online consultation.
Eligible patients can get a prescription through the Hims & Hers platform and receive FDA-approved Zepbound at $299 per month or Foundayo at $149 per month shipped to their home, rather than compounded copies.
Yes, the common share dividend was raised from $0.96 to $1.00 per share alongside its third quarter results, in which underlying EPS rose 10% to $2.05 but reported net income fell 29% to $785 million.